Premium
Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
Author(s) -
Eskazan Ahmet Emre
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31682
Subject(s) - dasatinib , medicine , myeloid leukemia , imatinib , tyrosine kinase inhibitor , chronic myelogenous leukemia , adverse effect , oncology , drug holiday , imatinib mesylate , leukemia , immunology , cancer , human immunodeficiency virus (hiv)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom